Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions

뉴스 본문을 불러오고 있어요.

Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions | 웨이프 WAPE

Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions

기사 요약

관련 종목

댓글 —